Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in...


Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in patients with advanced cancer after "impressive" preliminary data in a Phase I study. The early results suggest that the "drug can produce responses in patients with advanced cancer who have failed to respond to other therapies," says David Hong of the University of Texas. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs